Moderna, Inc. ( MRNA ) stock is trending on Friday. The company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for its RSV vaccine.

The Details: The RSV vaccine, mRNA-1345, is designed to protect adults aged 60 and older from respiratory disease caused by the RSV infection. As a result, the European Commission will authorize the vaccine.

The positive finding is based on data from the Phase 3 clinical trial ConquerRSV. The trial included 37,000 adults, aged 60 or older, and found an efficacy rate of 83.7% with 3.7 months of median follow-up against lower respiratory tract disease caused by RSV. The study also found sustained vaccine efficacy of 63.3% at a median follow up rate of 8.6 months.

“mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a pre-filled syringe to enhance ease of administration, which can save healthcare professionals time and reduce administrative errors,” said Stéphane Bancel, CEO of Moderna ( MRNA ).

The United States Food and Drug Administration approved the vaccine in May 2024 for adults 60 and older.

Analyst Changes: Several analysts have issued price target adjustments recently.

On Friday, Needham analyst Joseph Stringer reiterated Moderna ( MRNA ) with a Hold.

On Thursday, Evercore ISI Group analyst Cory Kasimov maintained Moderna ( MRNA ) with a In-Line and maintained a $120 price target.

Also on Thursday, Piper Sandler analyst Edward Tenthoff reiterated Moderna ( MRNA ) with a Overweight and maintained a $214 price target.

See Also: FDA Rejects Rocket Pharmaceuticals’ Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides

MRNA Price Action: At the time of writing, Moderna ( MRNA ) shares are trading 1.96% lower at $118.80 per data from Benzinga Pro.

Image: Lutsenko_Oleksandr on Shutterstock